Skip to main content

Devyser Diagnostics

Devyser Diagnostics AB is a Swedish diagnostic technology company developing DNA testing kits for hereditary diseases, oncology, and post-transplant monitoring. The company manufactures NGS diagnostic reagent kits enabling rapid target DNA sequencing, including Devyser Accept-cfDNA for transplant monitoring and Devyser BRCA for cancer risk screening. Main revenue drivers consist of commercial sales of diagnostic test kits and reagents alongside specialized clinical testing services. Devyser Diagnostics serves clinical genetics laboratories, hospital pathology departments, transplant centers, and oncology clinics across Europe, North America, and Asia. The company holds a specialized niche position in European NGS-based genetic testing and transplant monitoring diagnostics. Headquartered in Stockholm, Sweden, Devyser Diagnostics AB is listed on Nasdaq First North Premier Growth Market.

4 of the funds FundTelligence covers report a position in Devyser Diagnostics.

Legal name
Devyser Diagnostics AB
Sector
Health Care
Country
Sweden
Funds holding it
4
Exposure themes
Genetic Testing, Molecular Diagnostics, Precision Medicine & Genomics

Funds holding Devyser Diagnostics

Loading...